scholarly journals Transcriptomic signals in blood prior to lung cancer focusing on time to diagnosis and metastasis

2021 ◽  
Vol 11 (1) ◽  
Author(s):  
Therese H. Nøst ◽  
Marit Holden ◽  
Tom Dønnem ◽  
Hege Bøvelstad ◽  
Charlotta Rylander ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Metastatic Cancer ◽  
Case Control ◽  
Functional Genomic ◽  
Blood Samples ◽  
Lung Cancer Diagnosis ◽  
Time To Diagnosis ◽  
Genomic Signals ◽  
Nested Case Control

AbstractRecent studies have indicated that there are functional genomic signals that can be detected in blood years before cancer diagnosis. This study aimed to assess gene expression in prospective blood samples from the Norwegian Women and Cancer cohort focusing on time to lung cancer diagnosis and metastatic cancer using a nested case–control design. We employed several approaches to statistically analyze the data and the methods indicated that the case–control differences were subtle but most distinguishable in metastatic case–control pairs in the period 0–3 years prior to diagnosis. The genes of interest along with estimated blood cell populations could indicate disruption of immunological processes in blood. The genes identified from approaches focusing on alterations with time to diagnosis were distinct from those focusing on the case–control differences. Our results support that explorative analyses of prospective blood samples could indicate circulating signals of disease-related processes.

scholarly journals Predictive value of a series of inflammatory markers in COPD for lung cancer diagnosis: a case-control study

2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Cecilia Mouronte-Roibás ◽  
Virginia Leiro-Fernández ◽  
Alberto Ruano-Raviña ◽  
Cristina Ramos-Hernández ◽  
Pedro Casado-Rey ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Predictive Value ◽  
Inflammatory Markers ◽  
Case Control Study ◽  
Case Control ◽  
Lung Cancer Diagnosis ◽  
Control Study

The association between proton pump inhibitors (PPI) use for gastro-esophageal reflux disease (GERD) and lung cancer (LC): A nested case-control study.

2017 ◽  
Vol 35 (15_suppl) ◽  
pp. 1562-1562
Author(s):  
Hadas Dresler ◽  
Daniel Keizman ◽  
Ronac Mamtani ◽  
Maya Gottfried ◽  
Natalie Maimon ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Cancer Diagnosis ◽  
Case Control Study ◽  
Lung Cancer Risk ◽  
Case Control ◽  
Sensitivity Analyses ◽  
Diagnostic Code ◽  
Nested Case Control ◽  
Control Study

1562 Background: Data suggests that GERD with recurrent reflux and microaspiration of stomach contents, may be associated with lung injury, inflammation, activation of proliferative signals, and eventually DNA damage and malignant transformation. Recently, a large population based cohort study found that GERD may increase the risk of lung cancer in Asians. In the present nested case control study, we aimed to evaluate the association between PPI use as a surrogate for GERD and lung cancer in a large western population. Methods: We conducted a matched case-control study within a population-representative database from the United Kingdom. Study cases were defined as individuals with any diagnostic code of lung cancer. For every case, four eligible controls were matched on age, gender, practice site, time and duration of follow-up. Exposure of interest was PPI use prior to cancer diagnosis. Adjusted odds ratios (ORs) and 95% confidence intervals (CIs) for lung cancer were estimated using conditional logistic regression. Adjustment was performed for smoking. Results: The study population included 19143 lung cancer cases and 74473 matched controls. PPI use was associated with a significantly increased lung cancer risk (adjusted OR 1.70, 95%CI 1.64-1.77, p < 0.001). In a sensitivity analyses we observed similar associations when PPI use was initiated more than one year prior to cancer diagnosis (adjusted OR 1.18, 95%CI 1.13-1.23, p < 0.001) and more than two years prior to cancer diagnosis (adjusted OR 1.15, 95%CI 1.10-1.20, p < 0.001) Conclusions: ChronicPPI use, as a surrogate for symptomatic GERD, may be associated with a higher lung cancer risk.

scholarly journals Comparison of prediction models with radiological semantic features and radiomics in lung cancer diagnosis of the pulmonary nodules: a case-control study

2019 ◽  
Vol 29 (11) ◽  
pp. 6100-6108 ◽  
Author(s):  
Wei Wu ◽  
Larry A. Pierce ◽  
Yuzheng Zhang ◽  
Sudhakar N. J. Pipavath ◽  
Timothy W. Randolph ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Case Control Study ◽  
Prediction Models ◽  
Pulmonary Nodules ◽  
Case Control ◽  
Semantic Features ◽  
Lung Cancer Diagnosis ◽  
Control Study

scholarly journals Diagnostic Utility of Adenosine Deaminase in Serum and Bronchoalveolar Lavage Fluid for Screening Lung Cancer in Western Iran

2013 ◽  
Vol 32 (2) ◽  
pp. 109-115 ◽  
Author(s):  
Bahram Nikkhoo ◽  
Naseh Sigari ◽  
Bayazid Ghaderi ◽  
Abdolrahim Afkhamzadeh ◽  
Namam-Ali Azadi ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Adenosine Deaminase ◽  
Cancer Diagnosis ◽  
Bronchoalveolar Lavage Fluid ◽  
Screening Tool ◽  
Lavage Fluid ◽  
Control Group ◽  
Blood Samples ◽  
Lung Cancer Patients ◽  
Lung Cancer Diagnosis

Summary Background: This study aimed to determine adenosine deaminase (ADA) activity as a possible screening tool in lung cancer patients. Methods: Blood samples were collected from 30 subjects with positive pathological tests and 62 patients with negative pathological tests as a control group. The enzymatic activity of total ADA and its isoenzymes was determined. Results: tADA and ADA2 isoenzyme activity was significantly higher in cancerous patients compared to benign controls in serum and BAL fluid. Using a cut-off level of respectively 35.22 U/L and 31.80 U/L for BAL total ADA and ADA2, sensitivity and specificity were 100% and 81% for total ADA and 95% and 98% for ADA2. Conclusions: Adenosine deaminase may play important roles in the pathophysiology of lung cancer and because of its might be considered as a useful screening tool among the other markers in lung cancer diagnosis.

Antidepressant Prescription and Risk of Lung Cancer: A Nationwide Case-Control Study

2018 ◽  
Vol 52 (03) ◽  
pp. 134-141
Author(s):  
Chia-Jui Tsai ◽  
Wei-Che Chiu ◽  
Chia-Ju Chen ◽  
Pau-Chung Chen ◽  
Roger McIntyre ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Cancer Diagnosis ◽  
Case Control Study ◽  
Case Control ◽  
Cumulative Exposure ◽  
Defined Daily Dose ◽  
High Exposure ◽  
Lung Cancer Diagnosis ◽  
Antidepressant Prescription ◽  
Control Study

Abstract Introduction In recent decades, concern about safety of antidepressants has been raised but the risk between antidepressants and lung cancer has not yet been established. Methods A case-control study was conducted by using a nationwide database in Taiwan. The case groups were new onset lung cancer diagnosis during 1999–2008 and age- and gender-matched controls were selected among those without any cancer. The cumulative exposure dose before the lung cancer diagnosis was added and risks were calculated according to the levels of defined daily dose and classes of antidepressants. Results A total of 39,001 individuals with lung cancer and 189,906 individuals without lung cancer between 1999 and 2008 were included in the analysis. Antidepressants, of any class, were not associated with elevated risks for lung cancer with the exception of bupropion at high exposure levels (odds ratio=4.81, 95% confidence interval=1.39–16.71). Discussion Antidepressant prescription was not associated with elevation of lung cancer incidence using a nationally representative sample. The elevated risk for lung cancer with bupropion at high doses may be a bias by indication and warrant longitudinal investigation.

Computer-Aided Lung Cancer Diagnosis Approaches Based on Deep Learning

2018 ◽  
Vol 30 (1) ◽  
pp. 90 ◽  
Author(s):  
Peng Zhang ◽  
Xinnan Xu ◽  
Hongwei Wang ◽  
Yuanli Feng ◽  
Haozhe Feng ◽  
...  
Keyword(s):  
Lung Cancer ◽  
Deep Learning ◽  
Cancer Diagnosis ◽  
Lung Cancer Diagnosis ◽  
Computer Aided

Biased Lung Cancer Risk Perceptions: Smokers are Misinformed

2018 ◽  
Vol 238 (5) ◽  
pp. 395-421 ◽  
Author(s):  
Nicolas R. Ziebarth
Keyword(s):  
Lung Cancer ◽  
Cancer Risk ◽  
Cancer Diagnosis ◽  
Mortality Risk ◽  
Risk Perceptions ◽  
Lung Cancer Risk ◽  
Lifetime Risk ◽  
Lung Cancer Diagnosis ◽  
Cancer Risk Perceptions ◽  
Overall Mortality

Abstract This paper empirically investigates biased beliefs about the risks of smoking. First, it confirms the established tendency of people to overestimate the lifetime risk of a smoker to contract lung cancer. In this paper’s survey, almost half of all respondents overestimate this risk. However, 80% underestimate lung cancer deadliness. In reality, less than one in five patients survive five years after a lung cancer diagnosis. Due to the broad underestimation of the lung cancer deadliness, the lifetime risk of a smoker to die of lung cancer is underestimated by almost half of all respondents. Smokers who do not plan to quit are significantly more likely to underestimate this overall mortality risk.

Sign in / Sign up

Export Citation Format

Share Document